XML 90 R80.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segmental Reporting (Revenue by Product) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenue from External Customer [Line Items]        
Product sales $ 2,322.1 $ 1,476.2 $ 3,949.4 $ 2,899.4
Royalty Revenue 107.0 81.4 189.0 146.6
Royalties and Other revenues     189.0 146.6
Total revenues $ 2,429.1 $ 1,557.6 4,138.4 3,046.0
Other Royalties and Revenues [Member]        
Revenue from External Customer [Line Items]        
Royalties and Other revenues     56.8 49.1
SENSIPAR Royalties        
Revenue from External Customer [Line Items]        
Royalties and Other revenues     73.5 45.2
3TC and ZEFFIX Royalties        
Revenue from External Customer [Line Items]        
Royalties and Other revenues     27.1 18.0
FOSRENOL Royalties        
Revenue from External Customer [Line Items]        
Royalties and Other revenues     20.6 19.2
ADDERALL XR Royalties        
Revenue from External Customer [Line Items]        
Royalties and Other revenues     11.0 15.1
Genetic Diseases [Member]        
Revenue from External Customer [Line Items]        
Product sales     1,301.1 1,140.5
Genetic Diseases [Member] | ELAPRASE        
Revenue from External Customer [Line Items]        
Product sales     277.6 271.5
Genetic Diseases [Member] | FIRAZYR        
Revenue from External Customer [Line Items]        
Product sales     265.0 196.6
Genetic Diseases [Member] | REPLAGAL        
Revenue from External Customer [Line Items]        
Product sales     221.6 214.4
Genetic Diseases [Member] | VPRIV        
Revenue from External Customer [Line Items]        
Product sales     171.6 171.1
Genetic Diseases [Member] | CINRYZE        
Revenue from External Customer [Line Items]        
Product sales     337.2 286.9
Genetic Diseases [Member] | KALBITOR        
Revenue from External Customer [Line Items]        
Product sales     28.1 0.0
Neuroscience [Member]        
Revenue from External Customer [Line Items]        
Product sales     1,285.3 1,075.7
Neuroscience [Member] | VYVANSE        
Revenue from External Customer [Line Items]        
Product sales     1,026.9 841.6
Neuroscience [Member] | ADDERALL XR        
Revenue from External Customer [Line Items]        
Product sales     200.6 181.7
Neuroscience [Member] | Other Neuroscience [Member]        
Revenue from External Customer [Line Items]        
Product sales     57.8 52.4
Internal Medicine [Member]        
Revenue from External Customer [Line Items]        
Product sales     803.6 683.2
Internal Medicine [Member] | PENTASA        
Revenue from External Customer [Line Items]        
Product sales     136.9 145.0
Internal Medicine [Member] | GATTEX/REVESTIVE        
Revenue from External Customer [Line Items]        
Product sales     96.2 52.2
Internal Medicine [Member] | NATPARA        
Revenue from External Customer [Line Items]        
Product sales     35.5 5.9
Internal Medicine [Member] | Other Internal Medicine [Member]        
Revenue from External Customer [Line Items]        
Product sales     173.3 173.7
Internal Medicine [Member] | LIALDA/MEZAVANT        
Revenue from External Customer [Line Items]        
Product sales     361.7 306.4
Hematology [Member]        
Revenue from External Customer [Line Items]        
Product sales     349.6 0.0
Hematology [Member] | INHIBITOR THERAPIES [Member]        
Revenue from External Customer [Line Items]        
Product sales     74.0 0.0
Hematology [Member] | HEMOPHILIA        
Revenue from External Customer [Line Items]        
Product sales     275.6 0.0
Immunology [Member]        
Revenue from External Customer [Line Items]        
Product sales     189.5 0.0
Immunology [Member] | BIO THERAPEUTICS [Member]        
Revenue from External Customer [Line Items]        
Product sales     51.3 0.0
Immunology [Member] | IMMUNOGLOBULIN THERAPIES        
Revenue from External Customer [Line Items]        
Product sales     138.2 0.0
Oncology [Member]        
Revenue from External Customer [Line Items]        
Product sales     $ 20.3 $ 0.0